uniQure N.V. Variable Lease, Cost
uniQure N.V. (QURE) reported Variable Lease, Cost of $871.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-03-02
- uniQure N.V. variable lease, cost for the quarter ending 2020-12-31 was $154.00K, a 20.62% decline year-over-year.
- uniQure N.V. variable lease, cost for the quarter ending 2020-09-30 was $155.00K, a 18.32% increase year-over-year.
- uniQure N.V. variable lease, cost for the quarter ending 2020-06-30 was $153.00K, a 51.49% increase year-over-year.
- uniQure N.V. variable lease, cost for the quarter ending 2020-03-31 was $145.00K, a 3525.00% increase year-over-year.
- uniQure N.V. variable lease, cost for fiscal 2025 was $871.00K, a 23.39% decline from fiscal 2024.
- uniQure N.V. variable lease, cost for fiscal 2024 was $1.14M, a 8.16% decline from fiscal 2023.
- uniQure N.V. variable lease, cost for fiscal 2023 was $1.24M, a 57.71% increase from fiscal 2022.
- uniQure N.V. variable lease, cost for fiscal 2022 was $785.00K, a 12.46% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $871.00K 10-K · filed 2026-03-02 | |||
| 2024-12-31 | $1.14M 10-K · filed 2026-03-02 | |||
| 2023-12-31 | $1.24M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $785.00K 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $698.00K 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $309.00K derived: sum of 2 quarters · filed 2023-02-27 | $462.00K derived: sum of 3 quarters · filed 2023-02-27 | $607.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $155.00K 10-Q · filed 2020-10-27 | $308.00K derived: sum of 2 quarters · filed 2020-10-27 | $453.00K 10-Q · filed 2020-10-27 | $647.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $153.00K 10-Q · filed 2020-07-30 | $298.00K 10-Q · filed 2020-07-30 | $492.00K derived: sum of 3 quarters · filed 2022-02-25 | $623.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $145.00K 10-Q · filed 2020-04-29 | $339.00K derived: sum of 2 quarters · filed 2022-02-25 | $470.00K derived: sum of 3 quarters · filed 2022-02-25 | $571.00K derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $325.00K derived: sum of 2 quarters · filed 2022-02-25 | $426.00K derived: sum of 3 quarters · filed 2022-02-25 | $507.00K 10-K · filed 2022-02-25 |
| 2019-09-30 | $131.00K 10-Q · filed 2020-10-27 | $232.00K derived: sum of 2 quarters · filed 2020-10-27 | $313.00K 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $101.00K 10-Q · filed 2020-07-30 | $182.00K 10-Q · filed 2020-07-30 | ||
| 2019-03-31 | $4.00K 10-Q · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |